Selective inclusion/exclusion criteria led to low enrollment which was not viable for the sponsor and site.

The objective of the study is to evaluate the impact of a wireless smart insulin pen and smartphone-based bolus advisor on clinical and psychosocial outcomes in insulin-treated diabetes mellitus patients after 3 months of use.

The study is a prospective, randomized, controlled treatment design. The study device will be used for multiple daily injection (MDI) therapy of insulin. The participant will interact with the study device in the uncontrolled environment of the participant's daily life. The study protocol is designed to yield meaningful data to determine clinical and psychosocial benefits of using the study device. The study will evaluate the study device as an intervention versus a control group.

Inclusion Criteria:

1. The participant is ≥ 18 years of age
2. The participant has Type 1 OR Type 2 diabetes and is being treated with intensive insulin therapy via injection for ≥ 3 months. Intensive insulin therapy is defined as at least one long acting insulin dose and two or more short acting insulin doses per day.
3. Glycated hemoglobin (HbA1c) ≥ 7.5%).
4. The participant is a current iPhone user for over 30 days.
5. Participant adjusts meal insulin doses based on carbohydrate content of meals.
6. The participant is fluent in the English language.
7. The participant and the investigator understand participant obligations and agree that the participant is willing and able to complete the study visits.
8. Patients prandial insulin need must be <30 U per meal.

Exclusion Criteria:

1. The participant has been using unblinded CGM for less than 6 months.
2. The participant uses pre-mixed insulin.
3. Current use of a smart insulin pen.
4. Use of sliding scale insulin therapy that determines insulin dosages based exclusively on specific blood glucose results
5. Used systemic oral or inhaled steroids for more than 7 days within the last 3 months
6. Oral anti-diabetic agents, with the exception of metformin
7. Injectable anti-diabetic agents other than insulin
8. The participant is legally blind or has below specified best-corrected vision level.
9. Diagnosed with any clinically significant infectious disease or major organ system disease, such as gastroparesis or renal disease (at Investigator's discretion)
10. The participant is pregnant, lactating, or plans to become pregnant in the next 6 months.
11. The participant is currently participating in another clinical study that may preclude the participant from meeting the obligations of this study.
12. The participant has any additional condition(s) (medical, social, or psychosocial) that in the investigator's opinion would warrant exclusion from the study or prevent the participant from completing or complying with the study requirements.

Participants in the control arm will use a blinded device. All participants will be blinded to baseline time-in-range and HbA1c measures. Investigators will be blinded to professional CGM baseline time-in-range.